ArticleJournal of endocrinological investigation2026
Differential associations of traditional and shape-based adiposity indices with steatosis and fibrosis risk in metabolic dysfunction-associated steatotic liver disease.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTraditional anthropometric indices reflect total body adiposity, whereas novel shape-based indices capture fat distribution and unfavorable adiposity. How these measures relate to hepatic steatosis and fibrosis risk across the spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.
methodsIn this cross-sectional study, 222 patients with MASLD were included. Body mass index (BMI), waist circumference (WC), a body shape index (ABSI) and body roundness index (BRI) were evaluated. Hepatic steatosis was assessed by ultrasonography using the Bright Liver Echo Pattern (BLEP), while fibrosis risk was estimated using the Fibrosis-4 (FIB-4) index.
resultsBMI, WC, and BRI were higher in individuals with moderate-to-severe hepatic steatosis (BLEP ≥ 2), whereas ABSI did not differ according to steatosis severity. In multivariable logistic regression, BMI was independently associated with BLEP ≥ 2 (OR 1.19; 95% CI 1.05-1.35; p = 0.006), together with fasting glucose. ABSI showed a positive correlation with FIB-4 (r = 0.248; p < 0.001), whereas BMI did not. In multivariable linear regression, ABSI remained independently associated with FIB-4 (β = 0.145; p = 0.017), while BMI and BRI were not. Receiver operating characteristic analyses showed that BMI and WC best discriminated moderate-to-severe steatosis, whereas ABSI demonstrated the highest accuracy for identifying advanced fibrosis risk (FIB-4 ≥ 2.67; AUC 0.714; p = 0.004).
conclusionsTraditional and shape-based anthropometric indices capture complementary aspects of MASLD. Integrating measures of total adiposity and body shape may improve risk stratification in MASLD, although findings require confirmation using direct measures of liver fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.